103 related articles for article (PubMed ID: 22899853)
1. An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
Doran AC; Osgood SM; Mancuso JY; Shaffer CL
Drug Metab Dispos; 2012 Nov; 40(11):2162-73. PubMed ID: 22899853
[TBL] [Abstract][Full Text] [Related]
2. Diphenhydramine has similar interspecies net active influx at the blood-brain barrier.
Shaffer CL; Osgood SM; Mancuso JY; Doran AC
J Pharm Sci; 2014 May; 103(5):1557-62. PubMed ID: 24633923
[TBL] [Abstract][Full Text] [Related]
3. Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats.
Liu X; Cheong J; Ding X; Deshmukh G
Drug Metab Dispos; 2014 Apr; 42(4):482-91. PubMed ID: 24398459
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration.
Liu X; Smith BJ; Chen C; Callegari E; Becker SL; Chen X; Cianfrogna J; Doran AC; Doran SD; Gibbs JP; Hosea N; Liu J; Nelson FR; Szewc MA; Van Deusen J
Drug Metab Dispos; 2006 Sep; 34(9):1443-7. PubMed ID: 16760229
[TBL] [Abstract][Full Text] [Related]
5. Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574.
Shaffer CL; Hurst RS; Scialis RJ; Osgood SM; Bryce DK; Hoffmann WE; Lazzaro JT; Hanks AN; Lotarski S; Weber ML; Liu J; Menniti FS; Schmidt CJ; Hajós M
J Pharmacol Exp Ther; 2013 Oct; 347(1):212-24. PubMed ID: 23899905
[TBL] [Abstract][Full Text] [Related]
6. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid.
Liu X; Van Natta K; Yeo H; Vilenski O; Weller PE; Worboys PD; Monshouwer M
Drug Metab Dispos; 2009 Apr; 37(4):787-93. PubMed ID: 19116265
[TBL] [Abstract][Full Text] [Related]
7. Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates.
Nagaya Y; Nozaki Y; Kobayashi K; Takenaka O; Nakatani Y; Kusano K; Yoshimura T; Kusuhara H
Drug Metab Pharmacokinet; 2014; 29(5):419-26. PubMed ID: 24806821
[TBL] [Abstract][Full Text] [Related]
8. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys.
Tang C; Kuo Y; Pudvah NT; Ellis JD; Michener MS; Egbertson M; Graham SL; Cook JJ; Hochman JH; Prueksaritanont T
Biochem Pharmacol; 2009 Sep; 78(6):642-7. PubMed ID: 19481060
[TBL] [Abstract][Full Text] [Related]
9. Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats.
Mariappan TT; Kurawattimath V; Gautam SS; Kulkarni CP; Kallem R; Taskar KS; Marathe PH; Mandlekar S
Mol Pharm; 2014 Feb; 11(2):477-85. PubMed ID: 24380373
[TBL] [Abstract][Full Text] [Related]
10. Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats.
Lee KS; Chae SW; Park JH; Park JH; Choi JM; Rhie SJ; Lee HJ
Xenobiotica; 2013 Mar; 43(3):303-10. PubMed ID: 23205514
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
[TBL] [Abstract][Full Text] [Related]
12. Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.
Inoue T; Osada K; Tagawa M; Ogawa Y; Haga T; Sogame Y; Hashizume T; Watanabe T; Taguchi A; Katsumata T; Yabuki M; Yamaguchi N
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):156-62. PubMed ID: 22691713
[TBL] [Abstract][Full Text] [Related]
13. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein.
Wang JS; Ruan Y; Taylor RM; Donovan JL; Markowitz JS; DeVane CL
Int J Neuropsychopharmacol; 2004 Dec; 7(4):415-9. PubMed ID: 15683552
[TBL] [Abstract][Full Text] [Related]
14. Neuropharmacokinetics of two investigational compounds in rats: divergent temporal profiles in the brain and cerebrospinal fluid.
Tang C; Chen T; Kapadnis S; Hodgdon H; Tao Y; Chen X; Wen M; Costa D; Murphy D; Nolan S; Flood DG; Welty DF; Koenig G
Biochem Pharmacol; 2014 Oct; 91(4):543-51. PubMed ID: 25091561
[TBL] [Abstract][Full Text] [Related]
15. Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(-/-) rats.
Nagaya Y; Nozaki Y; Takenaka O; Watari R; Kusano K; Yoshimura T; Kusuhara H
Drug Metab Pharmacokinet; 2016 Feb; 31(1):57-66. PubMed ID: 26830080
[TBL] [Abstract][Full Text] [Related]
16. Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
Bundgaard C; Jensen CJ; Garmer M
Drug Metab Dispos; 2012 Mar; 40(3):461-6. PubMed ID: 22112383
[TBL] [Abstract][Full Text] [Related]
17. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats.
Aravagiri M; Marder SR
Psychopharmacology (Berl); 2002 Feb; 159(4):424-31. PubMed ID: 11823895
[TBL] [Abstract][Full Text] [Related]
18. In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy.
Loryan I; Melander E; Svensson M; Payan M; König F; Jansson B; Hammarlund-Udenaes M
Mol Psychiatry; 2016 Nov; 21(11):1527-1536. PubMed ID: 26809840
[TBL] [Abstract][Full Text] [Related]
19. [Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone].
Ding JJ; Jiao Z; Yu YQ; Shi XJ
Yao Xue Xue Bao; 2007 Jun; 42(6):631-8. PubMed ID: 17702401
[TBL] [Abstract][Full Text] [Related]
20. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.
Uchida H; Mamo DC; Pollock BG; Suzuki T; Tsunoda K; Watanabe K; Mimura M; Bies RR
Ther Drug Monit; 2012 Apr; 34(2):182-7. PubMed ID: 22377743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
